Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease
- Authors
- Cho Y.; Choi Y.I.; Oh S.; Han J.; Joo S.K.; Lee D.H.; Jung Y.J.; Kim B.G.; Lee K.L.; Kim W.
- Issue Date
- Mar-2020
- Publisher
- Springer
- Keywords
- Advanced fibrosis; Alcohol-related liver disease; Alcoholic steatohepatitis; Cirrhosis; Elasticity imaging technique; Laennec classification; Liver stiffness measurement; Noninvasive diagnosis; Point shear wave elastography; Ultrasonography
- Citation
- Hepatology International, v.14, no.2, pp.270 - 280
- Journal Title
- Hepatology International
- Volume
- 14
- Number
- 2
- Start Page
- 270
- End Page
- 280
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/19455
- DOI
- 10.1007/s12072-019-10009-w
- ISSN
- 1936-0533
- Abstract
- Background: Point shear wave elastography (pSWE) is a convenient noninvasive tool for assessing liver fibrosis in chronic liver disease. However, there is little information on the correlation between pSWE and the histological findings of alcohol-related liver disease (ALD). Thus, we investigated the diagnostic performance of pSWE in discriminating the fibrosis stage of patients with ALD. Methods: A total of 251 Korean patients with ALD were prospectively enrolled. The diagnostic performance of pSWE was evaluated on the basis of histological fibrosis severity according to Kleiner/Brunt et al.’s criteria and the Laennec classification. Results: Median liver stiffness on pSWE significantly increased as liver fibrosis stage increased (p < 0.001). Liver stiffness measurement proved to be an excellent diagnostic indicator in the evaluation of a ≥ F2 stage (area under the receiver operating characteristics curve [AUROC] 0.93; cutoff > 1.46 m/s), ≥ F3 stage (AUROC 0.90; cutoff > 1.47 m/s), and F4 stage (AUROC 0.91; cutoff > 1.66 m/s). Compared with noninvasive serum fibrosis tests, pSWE had the highest AUROC for predicting ≥ F2, ≥ F3, and = F4 stages and the highest Obuchowski index (0.931 ± 0.007; all p < 0.001). The AUROC for discriminating steatohepatitis from simple steatosis was 0.93 (> 1.49 m/s) and the AUROC for discriminating cirrhosis with steatohepatitis from cirrhosis without steatohepatitis was 0.92 (> 2.52 m/s). Conclusion: pSWE not only gives an accurate indication of liver fibrosis stage in ALD, but also can allow patients with severe alcoholic steatohepatitis to begin corticosteroid treatment without exposing them to the risks of liver biopsy. Clinical trial registration: Clincialtrials.gov Identifier NCT01943318. Graphic abstract: [Figure not available: see fulltext.]. © 2019, Asian Pacific Association for the Study of the Liver.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/19455)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.